The polymeric nanoparticles containing the monoclonal antibody trastuzumab, which interacts with the surface protein HER2 present on the surface of all breast cancer cells, start to concentrate in sites where HER2 is overexpressed in breast cancer cells. Here, ERBB2 is linked to breast carcinoma.